vai alle Pubblicazioni
Publications prior to 2004
Queste sono le pubblicazioni più recenti (2010). Per un elenco
completo andare su: http://www.ncbi.nlm.nih.gov/sites/entrez e
digitare : martelli am.
These are the most recent publications (2010). For a complete
list, log in to PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez)
and digit: martelli am.
Emerging MEK
Inhibitors.
J.A. McCubrey, L.A.
Steelman, S.L. Abrams, W.H. Chappell, S. Russo, R. Ove, M. Milella,
A. Tafuri, P. Lunghi, A. Bonati, F. Stivala, F. Nicoletti, M.
Libra, A.M. Martelli,
G. Montalto, M. Cervello.
Expert Opin. Emerg. Drugs 15:
27-47, 2010.
Morphological and biochemical patterns in skeletal
muscle apoptosis.
A. D'Emilio,
L. Biagiotti, S. Burattini, M. Battistelli, B. Canonico, C.
Evangelisti, P. Ferri, S. Papa, A.M. Martelli, E.
Falcieri.
Histol. Histopathol.25:
21-32, 2010.
The
phosphatidylinositol 3-kinase/Akt/mTOR signaling network and the
control of normal myelopoieis.
A.M.
Martelli, F. Chiarini, C.
Evangelisti, C. Grimaldi, A. Ognibene, L. Manzoli, A.M. Billi, J.A.
McCubrey.
Histol. Histopathol. 25:
669-680, 2010.
Identification of a functional nuclear export
sequence in diacylglycerol kinase-ζ
C.
Evangelisti, G. C. Gaboardi1, A.M.
Billi, A. Ognibene, K. Goto, P.L. Tazzari, J.A. McCubrey, A.M. Martelli.
Cell
Cycle 9:
384-388, 2010.
Erucylphosphohomocholine, the first intravenously
applicable alkylphosphocholine, is cytotoxic to acute myelogenous
leukemia cells through JNK- and PP2A-dependent
mechanisms.
A.M.
Martelli, V.
Papa, P.L. Tazzari, F. Ricci, C. Evangelisti, F. Chiarini, C.
Grimaldi, A. Cappellini, G. Martinelli, E. Ottaviani, P. Pagliaro,
S. Horn,
J. Bäsecke, L.H.
Lindner, H. Eibl, J.A. McCubrey.
Leukemia 24:
687-698, 2010.
Inositide signaling in the nucleus: From physiology
to pathology.
L. Cocco, M.Y. Follo,
I. Faenza, A. M. Billi, G. Ramazzotti, A.M. Martelli, L. Manzoli ,
G. Weber.
Adv Enzyme Regul.: in press, 2010: PMID: 19895834.
Nuclear inositide signaling in myelodysplastic
syndromes.
M. Follo, S.
Mongiorgi, C. Finelli, C. Clissa, G. Ramzzotti, I. Faenza, L.
Manzoli, A.M. Martelli,
L. Cocco.
J.
Cell. Biochem. 109:
1065-1071, 2010.
Dominant Roles of the Raf/MEK/ERK pathway in cell
cycle progression, prevention of apoptosis and sensitivity to
chemotherapeutic drugs.
L.S.
Steelman, S. L. Abrams J. G. Shelton, W. H. Chappell, J. Bäsecke,
F. Stivala, M. Donia, F. Nicoletti, M. Libra, A.M. Martelli, J. A.
McCubrey.
Cell
Cycle 9:
1629-1638, 2010.
The
Raf/MEK/ERK pathway can govern drug resistance, apoptosis and
sensitivity to targeted therapy.
S.L.
Abrams, L.S. Steelman, J.G. Shelton, E.W.T. Wong, W.H.Chappell, J.
Bäsecke, F. Stivala, M. Donia, F. Nicoletti, M. Libra, A.M. Martelli, J. A.
McCubrey.
Cell
Cycle 9:
1781-1789, 2010.
Enhancing therapeutic efficacy by targeting
non-oncogene addicted cells with combinations of signal
transduction inhibitors and chemotherapy.
S.L.
Abrams, L.S. Steelman, J.G. Shelton, W. Chappell, J. Bäsecke, F.
Stivala, M. Donia, F. Nicoletti, M. Libra, A.M. Martelli, J.A.
McCubrey.
Cell
Cycle 9
1839-1846: in press, 2010.
The
emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR
signaling network in normal myelopoieis and
leukemogenesis.
A.M.
Martelli, C. Evangelisti, F.
Chiarini, C. Grimaldi, A. Cappellini, A. Ognibene, J.A.
McCubrey.
Biochim. Biophys. Acta-Mol. Cell Res. :
in press, 2010.
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a
therapeutic target in acute myelogenous leukaemia.
A.M.
Martelli, C. Evangelisti, F.
Chiarini, J.A. McCubrey.
Oncotarget 2: in
press, 2010.